Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Mar 13;27(1):110.
doi: 10.1186/s13054-023-04397-7.

Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial

Miguel Ibarra-Estrada  1   2   3 , Eduardo Kattan  4   5 , Pavel Aguilera-González  6 , Laura Sandoval-Plascencia  7 , Uriel Rico-Jauregui  8 , Carlos A Gómez-Partida  8 , Iris X Ortiz-Macías  8 , José A López-Pulgarín  8 , Quetzalcóatl Chávez-Peña  8 , Julio C Mijangos-Méndez  8 , Guadalupe Aguirre-Avalos #  8 , Glenn Hernández #  4   5
Affiliations
Randomized Controlled Trial

Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial

Miguel Ibarra-Estrada et al. Crit Care. .

Abstract

Purpose: Methylene blue (MB) has been tested as a rescue therapy for patients with refractory septic shock. However, there is a lack of evidence on MB as an adjuvant therapy, its' optimal timing, dosing and safety profile. We aimed to assess whether early adjunctive MB can reduce time to vasopressor discontinuation in patients with septic shock.

Methods: In this single-center randomized controlled trial, we assigned patients with septic shock according to Sepsis-3 criteria to MB or placebo. Primary outcome was time to vasopressor discontinuation at 28 days. Secondary outcomes included vasopressor-free days at 28 days, days on mechanical ventilator, length of stay in ICU and hospital, and mortality at 28 days.

Results: Among 91 randomized patients, forty-five were assigned to MB and 46 to placebo. The MB group had a shorter time to vasopressor discontinuation (69 h [IQR 59-83] vs 94 h [IQR 74-141]; p < 0.001), one more day of vasopressor-free days at day 28 (p = 0.008), a shorter ICU length of stay by 1.5 days (p = 0.039) and shorter hospital length of stay by 2.7 days (p = 0.027) compared to patients in the control group. Days on mechanical ventilator and mortality were similar. There were no serious adverse effects related to MB administration.

Conclusion: In patients with septic shock, MB initiated within 24 h reduced time to vasopressor discontinuation and increased vasopressor-free days at 28 days. It also reduced length of stay in ICU and hospital without adverse effects. Our study supports further research regarding MB in larger randomized clinical trials. Trial registration ClinicalTrials.gov registration number NCT04446871 , June 25, 2020, retrospectively registered.

Keywords: Catecholamine sparing; Methylene blue; Norepinephrine; Randomized controlled trial; Septic shock; Vasopressin.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to disclose.

Figures

Fig. 1
Fig. 1
Flowchart of participants
Fig. 2
Fig. 2
Trends of mean arterial pressure and norepinephrine requirement along the first 4 days after recruitment. p values reflect the between subjects (groups) comparison test. * p < 0.05 between groups
Fig. 3
Fig. 3
Kaplan–Meier plot of the cumulative incidence of vasopressor discontinuation. Adjusted hazard ratio with death as a competing risk analysis. MB methylene blue, HR hazard ratio
Fig. 4
Fig. 4
Comparison of the change in monitoring values before initiation and after the last dose of intervention. p values reflect the between subjects (groups) comparison test. MB methylene blue, AST aspartate aminotransferase, ALT alanine aminotransferase
See this image and copyright information in PMC

Comment in

References

    1. Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascón GA, Hernandez G, Murray P, De Backer D. ADQI XIV workgroup THE ENDOTHELIUM IN SEPSIS. Shock. 2016;45:259–270. - PMC - PubMed
    1. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181–1247. - PMC - PubMed
    1. Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA. 2016;316:1298–1309. - PubMed
    1. Aya HD, Ster IC, Fletcher N, Grounds RM, Rhodes A, Cecconi M. Pharmacodynamic analysis of a fluid challenge. Crit Care Med. 2016;44:880–891. - PubMed
    1. Stolk RF, van der Pasch E, Naumann F, Schouwstra J, Bressers S, van Herwaarden AE, et al. Norepinephrine dysregulates the immune response and compromises host defense during sepsis. Am J Respir Crit Care Med. 2020;202:830–842. - PubMed

Publication types

Associated data